The Economics of Better Sleep

Historically, sleep has been treated as a symptom rather than a strategic healthcare target. Patients suffering from chronic pain, anxiety, depression, cardiovascular disease, or metabolic dysfunction frequently experience sleep disruption as well. Yet poor sleep can also worsen many of those same conditions, creating a cycle that increases healthcare utilization, medication burden, and overall costs.

For organizations operating under value-based reimbursement models, improving sleep may represent a rare opportunity to improve patient outcomes while reducing downstream spending.

Researchers increasingly view sleep as a key upstream determinant of health. Improvements in sleep quality have been associated with better physical health, mental health, cognitive performance, and chronic disease management — all areas healthcare systems are actively trying to improve.

This is particularly relevant as healthcare organizations become increasingly focused on prevention, measurable outcomes, and total cost of care. Unlike many health interventions that target a single symptom or disease state, sleep affects multiple dimensions of health simultaneously.

Why Cannabinoids Are Entering the Conversation

For decades, cannabis companies largely focused on retail markets. Success was measured by product sales, consumer demand, and market share. Healthcare, however, operates under a different standard.

"The largest opportunity for cannabinoids may be in healthcare, but adoption in healthcare will be driven by evidence," Lindquist says. "Clinicians, payers, and health systems need evidence to understand what a treatment does, who it helps, how safe it is, and whether its benefits are meaningful and reproducible."

That sentiment is shared by clinicians who have spent years on the front lines of sleep treatment. "After working in retail pharmacy for 10-plus years, if I had known back then that my patients could choose cannabis over Ambien or Xanax to help with sleep, I’d choose cannabis 10 out of 10 times," says Dr. Alan Ao, registered pharmacist and CEO of Vigor Dispensary via phone interview.

For Dr. Ao and others in pharmacy and clinical practice, the appeal isn't about dismissing conventional sleep medications outright — it's about giving physicians and patients another option, backed by data, when weighing the risks and tradeoffs of long-term use.

That shift toward evidence-based validation is beginning to reshape how some cannabinoid companies approach product development. Rather than relying solely on anecdotal reports, a growing number of organizations are investing in clinical research focused on specific cannabinoids and specific therapeutic applications.

One example comes from FloraWorks, which recently completed a randomized, placebo-controlled sleep study involving more than 1,000 participants evaluating CBN, a minor cannabinoid increasingly attracting interest from researchers studying sleep.

The company's findings are emerging alongside a growing body of independent research. Researchers at the University of Sydney's Lambert Initiative for Cannabinoid Therapeutics launched the CUPID study, a randomized, double-blind, placebo-controlled clinical trial examining CBN's effects on sleep and next-day function in patients with diagnosed insomnia. The study was designed to evaluate objective sleep measures — including sleep onset, wakefulness after sleep onset, sleep architecture, and next-day cognitive performance — areas that have historically lacked rigorous cannabinoid research.

More recently, University of Sydney researchers reported encouraging findings from the completed trial and identified CBN as a compound warranting larger-scale clinical investigation. The research reflects a broader shift underway across cannabinoid science, where investigators are increasingly studying individual cannabinoids as potential therapeutic compounds rather than evaluating cannabis as a single category.

These findings, from both academic and industry-led research, reinforce a broader trend: healthcare may ultimately evaluate cannabinoids the way it evaluates conventional therapeutics — by compound, by dose, and by clinical application, rather than as a single undifferentiated category.

The CMS Question

Perhaps the most important question is whether better sleep can reduce healthcare costs. That distinction could determine whether cannabinoid therapies remain consumer wellness products or evolve into meaningful healthcare interventions.

Federal initiatives such as CMS's Substance Access Beneficiary Engagement Incentive (BEI) program are beginning to explore frameworks for evaluating cannabinoid-based approaches under physician oversight. For healthcare leaders, the calculus is relatively straightforward:

• Can a cannabinoid intervention improve outcomes for a measurable percentage of patients?
• Can it do so safely?
• Can it reduce overall healthcare spending?

Value-based care organizations are asking themselves these questions every day. Healthcare executives evaluating emerging therapies are likely to focus on metrics such as responder rates, symptom improvement, medication changes, healthcare utilization, safety outcomes, and total cost of care. Those are healthcare system metrics, not traditional cannabis industry metrics.

Lindquist believes this is where the conversation around cannabinoids is beginning to change. Rather than asking whether cannabis belongs in healthcare, health systems may increasingly evaluate whether specific cannabinoids can produce measurable outcomes that justify broader adoption.

Looking Beyond Cannabis

One of the biggest misconceptions surrounding cannabinoids may be the assumption that they should be evaluated primarily through the lens of cannabis. Lindquist believes healthcare will increasingly view them through a different framework altogether.

"Healthcare does not need broad claims about cannabis," he says. "It needs to understand specific compounds, specific doses, and specific clinical applications."

That evolution mirrors what has happened across other therapeutic categories. Healthcare rarely adopts broad categories. It adopts validated interventions. If future research continues to demonstrate measurable outcomes in areas such as sleep, healthcare organizations may eventually view certain cannabinoids less as cannabis products and more as clinical tools.

That possibility creates a provocative question for both healthcare leaders and investors. What if the largest healthcare opportunity for cannabinoids isn't replacing existing treatments? What if it's helping solve one of healthcare's most expensive and pervasive underlying problems: poor sleep?

If sleep truly sits upstream of so many chronic conditions, improving it may create ripple effects across the healthcare system. If those improvements can be measured, replicated, and tied to lower costs, the future of cannabinoids may look far less like retail cannabis and far more like mainstream healthcare.